Literature DB >> 23902602

Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues.

Jian Zhu1, Yanping Wang, Yunhui Yu, Zheng Wang, Tingting Zhu, Xiukun Xu, Haiyan Liu, David Hawke, Dapeng Zhou, Yunsen Li.   

Abstract

BACKGROUNDS & AIMS: Glycosylation promoting or inhibiting tumour cell invasion and metastasis is of crucial importance in current cancer research. Tumour-associated carbohydrate antigens are predominantly expressed on the tumour cell surface. Glycosphingolipids (GSLs) are members of the family. To perform glycosphingolipidomic assays on neutral GSLs obtained from solid hepatocellular carcinoma (HCC) tissues and paired peritumoural tissues by linear ion trap quadrupole-electrospray ionization mass spectrometry.
METHODS: Qualitative and quantitative analysis of fucosylated neutral GSLs was performed in the positive ion mode on the LTQ-XL mass spectrometer and MALDI-TOF-MS.
RESULTS: A group of fucosylated neutral GSLs in HCC was found to be expressed higher in the tumour tissues, as their proportion in total cellular GSLs was 3.3-fold higher in the tumour tissues than in the peritumoural tissues (P < 0.01). Moreover, qualitative analysis of the aberrant fucosylated GSLs were completed, and seven types of fucosylated GSLs that contained terminal Fuca2Gal- structure were identified by mass spectrometry.
CONCLUSIONS: Our results may lead to improved immunotherapy of HCC and contribute to understanding the role of aberrant fucosylated GSLs in the development and progress of HCC in following studies.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer biomarker; glycomics; glycosphingolipidomics; hepatocellular carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23902602     DOI: 10.1111/liv.12265

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

Review 1.  Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma.

Authors:  Frances L Byrne; Ellen M Olzomer; Nina Lolies; Kyle L Hoehn; Marthe-Susanna Wegner
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

2.  FUT2 genetic variants as predictors of tumor development with hepatocellular carcinoma.

Authors:  Chih Tien Chen; Wen Ying Liao; Chia Chun Hsu; Kuan Chun Hsueh; Shun Fa Yang; Ying Hock Teng; Yung Luen Yu
Journal:  Int J Med Sci       Date:  2017-07-19       Impact factor: 3.738

3.  Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs.

Authors:  Lei Cheng; Shuhang Gao; Xiaobo Song; Weijie Dong; Huimin Zhou; Lifen Zhao; Li Jia
Journal:  Oncotarget       Date:  2016-09-20

Review 4.  Glycoproteomic and glycomic databases.

Authors:  Deniz Baycin Hizal; Daniel Wolozny; Joseph Colao; Elena Jacobson; Yuan Tian; Sharon S Krag; Michael J Betenbaugh; Hui Zhang
Journal:  Clin Proteomics       Date:  2014-04-13       Impact factor: 3.988

5.  On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging.

Authors:  E Ellen Jones; Shaalee Dworski; Daniel Canals; Josefina Casas; Gemma Fabrias; Drew Schoenling; Thierry Levade; Chadrick Denlinger; Yusuf A Hannun; Jeffrey A Medin; Richard R Drake
Journal:  Anal Chem       Date:  2014-08-08       Impact factor: 6.986

6.  High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma.

Authors:  Huan-Hsien Kuo; Ruey-Jen Lin; Jung-Tung Hung; Chung-Bao Hsieh; Tsai-Hsien Hung; Fei-Yun Lo; Ming-Yi Ho; Chau-Ting Yeh; Yen-Lin Huang; John Yu; Alice L Yu
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

7.  Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non‑small cell lung cancer.

Authors:  Soonbum Park; Jin-Muk Lim; Jung Nyeo Chun; Sanghoon Lee; Tae Min Kim; Dong-Wan Kim; Sang-Yeob Kim; Dong-Jun Bae; Sang-Mun Bae; Insuk So; Hong-Gee Kim; Ji-Yeob Choi; Ju-Hong Jeon
Journal:  Int J Oncol       Date:  2019-12-24       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.